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Abstract
Introduction: Autologous peripheral blood hematopoietic progenitor cell collection
(A-HPCC) in children typically requires placement of a central venous catheter
(CVC) for venous access. There is scant published data regarding the performance
and safety of femoral CVCs in pediatric A-HPCC.
Methods: Seven-year, retrospective study of A-HPCC in pediatric patients collected
between 2009 and January 2017. Inclusion criteria were an age 21 years and A-
HPCC using a femoral CVC for venous access. Femoral CVC performance was
examined by CD34 collection rate, inlet rate, collection efficiency (MNC-FE, CD34-
FE), bleeding, flow-related adverse events (AE), CVC removal, and product sterility
testing. Statistical analysis and graphing were performed with commercial software.
Results: A total of 75/119 (63%) pediatric patients (median age 3 years) met study crite-
ria. Only 16% of children required a CVC for 3 days. The CD34 collect rate and CD34-
FE was stable over time whereas MNC-FE decreased after day 4 in 80% of patients.
CD34-FE and MNC-FE showed inter- and intra-patient variability over time and appeared
sensitive to plerixafor administration. Femoral CVC showed fewer flow-related AE com-
pared to thoracic CVC, especially in pediatric patients (6.7% vs. 37%, P5 0.0005;
OR5 0.12 (95%CI: 0.03-0.45). CVC removal was uneventful in 73/75 (97%) patients
with hemostasis achieved after 20–30 min of pressure. In a 10-year period, there were no
instances of product contamination associated with femoral CVC colonization.
Conclusion: Femoral CVC are safe and effective for A-HPCC in young pediatric
patients. Femoral CVC performance was maintained over several days with few
flow-related alarms when compared to thoracic CVCs.
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1 | INTRODUCTION
Adequate venous access can be challenging in pediatric
patients undergoing autologous peripheral blood hematopoi-
etic progenitor cell collection (A-HPCC). Most pediatric
patients require a central venous catheter (CVC) to establish
and maintain adequate blood flow for cell separation.1,2 In
older children and adults requiring CVC access, the preferred
catheter is a double-lumen, polyurethane CVC placed in the
subclavian vein or internal jugular.3 In very small children,
however, the rigidity and size of polyurethane CVC relative
to patient anatomy increases the difficulty and potential risks
associated with thoracic CVC.1 To avoid polyurethane
CVCs, some centers have used soft, silicone-type CVC for
pediatric A-HPCC. Unfortunately, silicone-based catheters are
prone to collapse, with an increasing risk of mechanical occlu-
sion at small sizes.1 In addition, A-HPCC using some tun-
neled silicone-type catheters still requires a peripheral
intravenous catheter (PIV) for return to avoid recirculation due
to the close proximity of the draw and return lumens.4 Finally,
long-term catheters have in increasing risk of infection, cathe-
ter dysfunction, and thrombosis in 10–74% of patients.5–8
Our institution has routinely used short-term femoral
CVC in young pediatric patients undergoing A-HPCC.
Patients undergo femoral line placement the morning of their
first scheduled A-HPCC, followed by line removal 6–24 h
after their last procedure. In critically ill children, femoral
CVCs have a low rate of insertion-related complications, but
are reported to have a higher rate of mechanical obstruction
and thrombosis.9,10 Likewise, at least one institution has
anecdotally reported a high rate of catheter occlusion during
A-HPCC in children younger than 3 years of age.11 Femoral
CVCs are also associated with a higher incidence of infec-
tion.12,13 As a quality assurance project, we performed a 7
year review of femoral CVC performance on CD34 collec-
tion, product sterility, and procedure-related adverse events
(AE) in pediatric patients undergoing A-HPCC.
2 | MATERIALS AND METHODS
2.1 | Patients and study design
The study was a 7-year retrospective review of A-HPCC in
pediatric patients at the University of Michigan between
January 1, 2009 and January 31, 2017: Earlier collections
were excluded due to the lack of consistent peripheral
CD34 counts after Day 1 and incomplete documentation of
catheter-related issues during leukapheresis. Inclusion criteria
included: (1) age 21 years at the time of A-HPCC; (2) a
double-lumen, femoral CVC for venous access; and (3) leuka-
pheresis using either the COBE Spectra® or SPECTRA Optia
and CMNC program (TerumoBCT, Lakewood, CO). Patients
collected on the SPECTRA Optia using the MNC program
were excluded because of internal data showing decreased col-
lection efficiencies in children requiring a blood prime.14
Among 119 pediatric patients who underwent A-HPCC, 75
met inclusion criteria. Forty-four patients were excluded due
to alternative CVCs (n5 19: 10 subclavian and 9 internal jug-
ular), peripheral IV access (n5 18), and collection using the
SPECTRA Optia and MNC program (n5 7).
Primary data elements included: patient demographics
(age, weight, diagnosis); mobilization (chemotherapy,
growth factors [Granulocyte colony-stimulating factor, G-
CSF; Granulocyte-macrophage colony-stimulating factor,
GM-CSF], plerixafor); laboratory studies (peripheral blood
WBC, platelet count, MNC and CD34 counts) number of
leukapheresis procedures, fractional collection efficiencies
(FE), inlet rate (mL/minute, mL/minute/kg) and product cha-
racteristics (cell yields, sterility testing). Catheter-specific
information included a review of the operative procedure
note for CVC size, manufacturer and adverse events (AE).
Catheter-related issues impacting A-HPCC were identified
from the procedure record and product master file. As previ-
ously published,15 CVC-related AEs during A-HPCC were
defined as bleeding; catheter dysfunction requiring repeated
flushing, line reversal, instillation of anti-thrombolytics, or
use of alternate venous access; slow inlet rate (<0.7
mL min21 kg21); difficulty in establishing or maintaining an
interface, circuit clotting and early termination of procedures.
Femoral CVC performance was compared to a small cohort
of pediatric (n5 19) and adult myeloma patients (n5 19)
who underwent A-HPCC with thoracic CVC.
2.2 | Femoral CVC
Patients underwent femoral CVC placement under general
anesthesia the morning of their first scheduled leukapheresis
collection. Catheter care was per institutional guidelines.16
Following each apheresis session, catheter lines were flushed
with 5 mL saline, followed by heparin (1:1000 U mL21,
0.9–1.3 mL fill volume) and then capped. Femoral CVCs
were removed within 6–24 h of the last A-HPCC. Criteria
for removal included a platelet count of 50 K lL21 and
correction of coagulation studies to assure the absence of
residual citrate effect. Patients with a post-procedure platelet
<50 K lL21 were transfused with platelets prior to line
removal. Lines were removed at the patient bedside by
Blood and Marrow Transplant (BMT) staff or in the operat-
ing room in coordination with other procedures. Following
removal, patients were observed for a minimum of 1 h with
activity restrictions for at least 6 h. Patients were advised to
avoid bathing or showering for up to 24 h after CVC
removal.
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2.3 | HPC collection and processing
All patients underwent large volume leukapheresis (LVL, 3
blood volumes) using either the COBE Spectra and WBC
collection set or SPECTRA Optia and CMNC software as
previously described.15,17 Cell counts were performed on the
Sysmex XE 5000 (Sysmex, Kobe, Japan). The WBC differ-
ential was determined manually. Peripheral CD34 counts and
product yields were determined by flow cytometry, as rec-
ommended by the International Society of Hematology and
Graft Engineering with modification.18,19 Cells were volume
adjusted and frozen in 10% dimethyl sulfoxide as previously
described.17,18 All cell processing was performed in biosaf-
ety hoods, located within a certified clean room.
2.4 | Sterility testing and positive cultures
Sterility testing of each product was performed before and
after processing using the USP culture method per 21 CFR
610.12.20 All positive cultures were investigated and findings
documented in the product record and master excel file.
Recorded data included: culture results from the patient
and product (pre- and post-processing); identification of the
microorganism, date of positive culture; and presence/
absence of infusion reactions.
2.5 | Data analysis
Quantitative data were reported as the mean6 standard devi-
ation (SD) unless noted otherwise. Variables with wide inter-
patient values were reported as mean, median and range.
CD34 and MNC fractional efficiencies (CD34-FE, CD34-
FE) were calculated as described, where FE5 total cell
yield/(pre-procedure peripheral cell count) 3 (total blood
volume processed).21 Categorical data were analyzed by v2
and odds ratio using EpiInfo (Center for Disease Control,
Atlanta, GA). Linear regression, t test (paired, unpaired),
and graphics were performed with commercial software
(Kaliedograph®, Synergy Software, Reading, PA). A P val-
ues< 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Patient demographics
A total of 119 pediatric patients underwent A-HPCC bet-
ween 2009 and January 2017. Eighty-two patients (69%)
underwent leukapheresis using a femoral CVC. Seven
patients were excluded due to A-HPCC collection on the
SPECTRA Optia and MNC program. In total, 75 patients
(63%) and 119 procedures were eligible for further study.
The median patient age was 3 years (range, 10 months to 17
years), with 25% and 69% of children <3 and 5 years of
TABLE 1 Patient demographics
Variable No. patients (%)
No. patients 75
Sex (M/F) 37/38
Age, yearsa
(median, range)
4.86 4.0 (3, 0.8–17)
2 years (%) 19 (26%)
5 years (%) 52 (70%)
>5 years (%) 22 (30%)
Weight, kga
(median, range)
21.86 15.8 (16.4, 8–97)
10 kg (%) 8 (11%)
20 kg (%) 51 (69%)
>20 kg (%) 23 (31%)
Primary diagnosis (%)
Neuroblastoma 45 (60%)
CNS malignancy 17 (23%)
Lymphoma 5 (7%)
Hepatoblastoma 2 (2.7%)
Ovarian carcinoma 2 (2.7%)
Ewing’s sarcoma 2 (2.7%)
Germ cell tumor 1 (1%)
Nephroblastoma 1 (1%)
Mobilization (%)
Chemotherapy 74 (99%)
Cytokine-only 1 (1%)
Plerixafor 12 (16%)
GM-CSF 2 (3%)
CD34 target yields (%)
10–15 3 106/kg 62 (83%)
3 3 106/kg 13 (17%)
Femoral CVC placement (%)
Right 70 (95%)
Left 4 (5%)
Platelet transfusionb 40 (54%)
CVC brandc (%)
medCOMP 26 (35%)
Mahurkur 26 (35%)
Arrow international 15 (20%)
Unknown 8 (10%)
No. HPCC procedures/patient (%)
1 53 (71%)
2 10 (13%)
3 or more 12 (16%)
amean6SD.
bNo. patients requiring a platelet transfusion before femoral CVC placement.
cMahurkar, Covidein, Mansfield, MA; medCOMP, Haleysville, PA; Arrow
International, Reading, PA.
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age, respectively (Table 1). Most children (74/75) were col-
lected following mobilizing chemotherapy. The majority of
patients (84%) required only 1–2 procedures.
Twelve patients required three to six procedures to collect
sufficient cells for transplant (Table 2). Patients requiring three
ormore procedures were generally older (median age, 9.5 years),
with delayed marrow recovery (WBC> 5 K lL21) following
cancer-specific chemotherapy (18.16 1.5 days versus 13 days,
cyclophosphamide, P5 0.06). Several patients required an
increase in G-CSF dosing (7/12, 58%), often supplemented with
GM-CSF (2/12, 17%) and/or plerixafor (11/12, 92%).
3.2 | Laboratory studies
The mean peripheral WBC on Day 1 was 236 17 K lL21
(median, 15.3 K lL21; range, 4.6–84.4 K lL21), which
continued to slowly increase over time (Table 3; Figure 1S,
Supporting Information). The mean absolute MNC count on
Day 1 was 3.66 2.3 K lL21 (range, 0.5–10.6 K lL21) with
the highest counts on Day 3. The mean peripheral CD34
counts were highest on Day 1 (3336 49/lL SEM; median,
199; range, 1–1,740/lL: P< 0.0001) due to a large cohort of
well-mobilized young children. As a result, 71% of patients
collected in a single procedure. Patients who required two or
more procedures had significantly lower peripheral CD34
counts on subsequent days (Table 3). The mean pre-procedure
platelet count was also highest on Day 1 (95 K lL21, range,
35–253 K lL21; P5 0.003) but fell 24–29% due to
procedure-related platelet losses (Table 3, Supporting Informa-
tion Figure S1). Six patients required a total of 10 additional
platelet transfusions during the course of A-HPCC (Days 3–5)
for procedure-related platelet losses (Table 3).
TABLE 2 Patients who required three or more A-HPCC procedures
Mobilization regimen CD34/kg yields per procedure day
Pt.
No.
Age/
Sex Diagnosisa
Mobilizing
chemotherapya
G-CSF
(lg kg21
day21)b
Plerixafor
(Day)c 1 2 3 4 5 6
7 5/F Hepatoblastoma ICE 10–> 17 1–2 0.3 1.4 1.5 – – –
17 13/M Pineal Germ
Cell Tumor
Cisplatin
Cyclophosphamide
10–> 20 1–3c 0.7 0.9 3.8 4.9 – –
19 12/M Medulloblastoma Cyclophosphamide 10–> 14 1–3 0.2 1.8 1.2 1.2 – –
21 3/M Lymphoma (NHL) Cyclophosphamide 10 3 0.5 0.4 0.8 1.4 – –
25 5/M Neuroblastoma ICE 10–> 18 1–2 0.5 0.5 0.9 – – –
32 15/F Lymphoma (NHL) R-ICE 10 4–6d 0.2 – – 0.8 0.9 0.9
43 9/F Ovarian Cancer ABVE
Cisplatin
Cyclophosphamide
10–> 20 none 0.9 1.1 2.6 – – –
45 4/F PNET ACNS 0333 10–> 16,
1GM-CSF
2–5 0.2 0.2 0.5 1.3 4.1 3.7
48 2/F Neuroblastoma IE 10–> 20 1–2 0.6 2.5 4 – – –
49 11/M Medulloblastoma Cisplatin
Lomustine
Vincristine
10 1–2 1.7 2.2 3.8 – – –
50 10/F Ovarian mixed
germ cell tumor
Cyclophosphamide 10 2–4c 0.3 0.7 0.4 1.7 1.3 –
55 13/M Lymphoma (HL) ICE 10,
1GM-CSF
2–4c 0.2 0.5 1.7 1.9 – –
aAbbreviations: –, not performed. ABVE, adriamycin, bleomycin, vincristine, etoposide; ACNS 0333; cisplatin, etoposide, cyclophosphamide, vincristine, metho-
trexate; IE/ICE/R-ICE, ifosphamide, carboplatinum, etoposide6 rituximab (R); NHL, non-Hodgkin’s lymphoma; PNET, primitive neuroectodermal tumor;.
bDaily G-CSF dose at time of first A-HPCC. Several patients had an increase in dose (–>) during course of A-HPCC.
cDay plerixafor administered for A-HPCC the next day. In general, plerixafor was administered in the early evening (8 pm), 12 h prior to scheduled leukaphere-
sis as recommended in the package insert. In two patients (17 and 50), the first dose of plerixafor administration was inadvertently administered after midnight. In
Patient 55, plerixafor was actually given the morning of Day2, an hour prior to leukapheresis. The first effective dose, therefore, is Day 3.
dPatient 32 did not undergo A-HPCC on days 2 and 3 due to low CD341 counts and evidence of persistent delayed marrow recovery.
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3.3 | Femoral line characteristics
All patients had a femoral line placed under anesthesia with-
out complication. Fifty-three percent of patients required a
platelet transfusion prior to CVC placement (Table 1). Most
children had CVC placed in the right femoral vein (95%):
Four children had left-sided femoral CVC due to anatomic
issues and tumor involvement. Details regarding the CVC
size and manufacturer were available in 67 (89%) patients
(Table 1).
The median CVC size for all patients was 10 French
(range, 7–14). In young children (<5 years), the median cathe-
ter size was 10 French (range, 7–12) including 50% of children
under 3 years of age (Figure 1A). In children older than 5 years,
the vast majority required a 12 French CVC or larger. When
examined by patient weight (Figure 1B), the median CVC size
was as follows: <10 kg (8 French; range, 7–8), 10–20 kg (10
French; range, 7–12) and> 20 kg (12 French, range, 7–14).
3.4 | Femoral line performance
Femoral CVC performance over the course of A-HPCC was
also examined. CVC performance was analyzed relative to
average inlet rates, cell collection rates, cell collection effi-
ciency, and access-related AE.
3.4.1 | Inlet rate
The average inlet rate was 27.76 18.3 mL min21. When
corrected for body weight, the mean inlet rate per procedure
was 1.16 0.43 mL min21 kg21. Only 20% of procedures
were performed at an inlet rate <0.9 mL min21 kg21 (Figure
2A; range, 0.7–0.89). The highest mean inlet rate was Day 3
(1.36 0.79 mL min21 kg21, P5 0.37), but then progres-
sively decreased over the next 3 days (Figure 2B). There was
no correlation between inlet rates and either the peripheral
WBC count or platelet counts (data not shown).
TABLE 3 A-HPC collection by day
Procedure day
All procedures Day 1 Day 2 Day 3 Days 4–6
A-HPCC
No. procedures 119 75 22 12 10
No. patients 75 75 22 12 7
Median age (years) 3 3 6 8.5 12
Median weight (kg) 16.4 16.4 20.8 29.5 42
Total blood volume (mLa)
(median, range)
1,7936 1,062
(1286,530–4984)
1,5666 1,025
(1,611)
1,9096 966
(1,909)
2,3726 1,029
(2,738)
1,7936 1,062
(2,545)
Liters processeda
(median, range)
4.36 3.5
(3.8, 1.2–22.5)
4.66 3.4
(3.5)
5.66 2.9
(4.1)
7.26 3.8
(7.2)
7.76 3.9
(8.7)
Median BV processed 3 3 3 3 3
Total inlet rate (mL min21)a 27.76 18.3 236 14.7 326 19.8 41.16 26.6 35.66 16.2
Adjusted inlet ratea
(mL kg21 min21)
1.16 0.43 1.096 0.37 1.146 0.42 1.36 0.79 0.986 0.14
Pre-peripheral blood counts
WBC (109/L)a 24.76 16.8 22.76 17.3 246 14.3 33.16 17.6 31.36 13.2
%MNCa 7.56 10.6 18.96 11.6 166 8.2 15.86 8.9 12.96 7.7
MNC (109/L)a 3.66 2.3 3.36 2.7 3.56 2.7 4.56 2.7 3.46 1.6
CD34 (per lL)b 224.36 34.4 333.16 48.9c 32.16 8.5 13.16 7.1 23.56 7.2
Platelet (1011/L)a 96.96 44.3d 736 32.3 75.36 35.4 69.16 30.6
Cell Yields
CD34/kg (3106)a 23.56 35.8 35.66 40.5c 46 4.5 1.86 1.3 2.26 1.4
MNC/kg (3108)a 3.36 2.2 3.16 2.3 3.36 2.3 4.56 2.3 3.56 1.9
Platelet transfusions 78 52 10 7 9
Preprocedure 50e 40e 4 3 3
CVC removal 28 12 6 4 6
aResults are mean6SD.
bResults are mean6SEM.
cPeripheral CD34/lL and CD34/kg significantly higher on Day 1 (P< 0.0001).
dPeripheral platelet count significantly higher on Day 1 (P5 0.003).
eForty patients received a platelet transfusion prior to femoral CVC insertion (see Table 1).
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3.4.2 | CD34 collection and cell yields
CD34/kg yields were greatest on Day 1 due to a large cohort
of well-mobilized young children (mean, 35.66 40 3
106/kg; P< 0.0001: Table 3). As expected, there was a linear
correlation between the peripheral CD34 count and the
CD34/kg yield (Figure 2C, insert; R5 0.90). We also exam-
ined the CD34 collection rate on Day 1 to subsequent proce-
dures (Days 2–6). As shown in Figure 2C, there was no fall-
off in CD34 collection with subsequent days.
A CD34-FE was available in 111/119 (93%) procedures.
The mean CD34-FE for all collections was 0.596 0.30 and
was relatively stable over the course of A-HPCC (Figure 2D;
range, 0.54–0.59; P5 0.42–0.90). There was also no differ-
ence in CD34-FE in patients with left-sided femoral CVC
(0.506 0.19 versus 0.596 0.32, right; P5 0.37). There was
no significant correlation between CD34-FE and peripheral
WBC count or platelet count (data not shown).
3.4.3 | MNC collection and cell yields
The mean MNC was 3.36 2.2 3 108/kg with the highest
yield on Day 3 (4.56 1.9, P5 0.07; Table 3). There was a
weak linear correlation between MNC/kg and peripheral
MNC count (y5 1.31 0.56x, R5 0.58). There was no dif-
ference in the slope or rate of MNC collection rate between
Day 1 and subsequent days (Figure 2E).
The mean MNC-FE for all collections was 0.556 0.44
(range, 0.11–1.8) and inversely related to absolute MNC
count (y5 0.8620.66 logx, R520.47; data not shown).22
Although the median MNC-FE was relatively stable over
time (Figure 2F), there was a trend toward improved MNC-
FE on Day 2 (0.726 0.16, P5 0.12), with 50% of all
patients showing an increase in MNC-FE (Figure S2, Sup-
porting Information). By Day 4, MNC-FE (0.406 0.24,
P5 0.37) fell by 10–73% in 80% of patients (Supporting
Information Figure S2) and mirrored the drop in inlet rate.
3.4.4 | Line-associated adverse events
during A-HPCC
Ten bleeding and/or flow-related AE were documented in
eight patients for an overall rate of 8% per procedure and
11% per patient (Table 4). Two patients had mild oozing on
Day 1 that was easily controlled by a pressure dressing. In a
third patient, there was significant oozing on Day 3 that was
unresponsive to pressure and required application of a topical
clotting agent and platelet transfusion (pre-procedure platelet
count5 44 K lL21). It was subsequently determined that the
line had dislodged a short distance.
Five patients had alarms and flow-related issues over the
course of A-HPCC. Three patients required either repeated
line flushing (n5 2) or line reversal (n5 2) on Day 2. While
both patients who required line reversal experienced a dec-
rease in CD34-FE (22%, 60%) relative to Day 1, there was
no clinical evidence of recirculation per nursing notes. One
patient developed new and significant difficulties in estab-
lishing an interface on Day 4 that prolonged the procedure
by 30–40 min. Another patient experienced a 30% decrease
in flow rate (0.7 mL min21 kg21) on Day 6.
3.5 | Comparison of femoral and thoracic
CVC in pediatric A-HPCC
We also compared the performance of femoral CVC to a
small cohort of 19 pediatric patients who underwent A-
HPCC using thoracic CVC (n5 9 internal jugular, n5 10
subclavian; 33 procedures) during the same time interval.
Patients with thoracic CVC were significantly older (136
6.6 years, range, 1–21 years; P< 0.0001) and heavier (586
32 kg; range, 10–122 kg; P5 0.0002) than patients with
femoral CVC. The most common diagnosis in these patients
was lymphoma (47%), followed by brain cancer (21%), neu-
roblastoma (16%), testicular carcinoma (11%), and Ewing’s
sarcoma (5%). Because some patients had CVC placed at
FIGURE 1 Distribution of femoral CVC size by patient age (A) and weight (B)
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outside facilities, the catheter size was only available in 81%
of patients. The median thoracic CVC size was 12 French
(range, 6–14). In children under 20 kg, a 6 to 7 French CVC
was placed (n5 3).
In terms of catheter performance, the total mean inlet rate
with thoracic CVC was 446 20 mL min21. When corrected
for body weight, however, thoracic CVC had a slower inlet
rate than femoral CVC (0.926 0.31 mL min21, P5 0.02:
Figure 2A). The mean CD34-FE (0.516 0.20 versus 0.59
femoral, P5 0.18) and MNC-FE (0.486 0.28 versus 0.55
femoral) was 13–15% lower than femoral CVC, although the
difference was not statistically significant (P5 0.18–0.41).
FIGURE 2 Femoral CVC performance. (A) Distribution of inlet rate/minute/kg by patient weight in pediatric patients with femoral CVC (black) and
thoracic CVC (gray). (B)Mean inlet rate by day. (C) CD34 collection rate (CD34 yield per peripheral CD34 count) comparing Day 1 (—·—) versus subse-
quent days (Day 2–6, - -- -). Insert, CD34 collection rate for all procedures. (D) CD34-FE for all patients by procedure day. (E)MNC collection rate com-
paring Day 1 (—·—) versus Days 2–6 (–o–). (F) MNC-FE for all patients by procedure day. The number of procedures per day is listed in Table 3. Data in
figures D and F are box plots, showing the median, 25th and 75th percentile, bracketed lines are the minimum andmaximum values based on the interquar-
tile range (IQR). Values exceeding 3IQR are outliers and are denoted by open circles
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Among 7/19 patients who underwent multiple A-HPCC with
thoracic CVC, there was a drop in both CD34-FE (0.38 vs.
0.55 Day 1; P5 0.18, paired t-test) and MNC-FE (0.43 vs.
0.52 Day 1, P5 0.37) by the second or third procedure.
A comparison of access-related AE by CVC type indi-
cated a substantially lower incidence (6.7% vs. 37%, P5
0.0005) and risk for flow-related AE with femoral CVC
(OR5 0.12; 95% CI, 0.03–0.45) (Table 4). We also com-
pared the incidence of CVC-AE in pediatric patients to an
equivalent cohort of adult multiple myeloma patients (19/81
patients),15 who also underwent A-HPCC using thoracic
CVC (Table 4). As shown in Table 4, pediatric patients with
thoracic CVC also had higher flow-related AE rates than
their adult counterparts (37% vs. 16%, P 50.14). In both
pediatric and adult patients, flow related AE associated with
thoracic CVC tended to be more severe than femoral CVC,
including placement/use of alternate IV access, recirculation,
circuit clotting, and aborted procedures.
3.6 | Catheter performance in individual
patients over time
Although the mean CD34-FE was stable over time, there
was significant inter- and intra-patient variability between
collections (Figure 2S, Supporting Information). Because
there was a trend toward decreasing inlet rate and MNC-FE
after Day 3, we performed a detailed analysis of cell collec-
tion in 12 patients who required three or more procedures.
Nine patients had complete data for all A-HPCC: In three
patients, a preprocedure peripheral CD34 count was not per-
formed on one or more days. As shown in Figure 3, CD34-
FE varied over the course of collection and was unique for
each patient. All patients successfully collected sufficient
cells for transplant (Table 2).
Interestingly, there was an apparent drop in CD34-FE in
several patients within 12 to 24 h after receiving the first
dose of plerixafor (patients 7, 17, 21, 32, 45, 48, 49, and 55).
Even though all patients showed a progressive increase in
WBC over the course of A-HPCC, particularly after receiv-
ing plerixafor, there was no clear relationship between WBC
and CD34-FE. In fact, the highest WBC was 30 K lL21
in 6/9 evaluable patients. There was also no correlation bet-
ween CD34-FE and either the pre-procedure platelet count or
recent platelet transfusion (data not shown).
Finally, we compared the course of CD34-FE with
MNC-FE in 10 patients (Figure 4A). In general, the MNC-
FE declined over the course of A-HPCC. Surprisingly, the
CD34-FE and MNC-FE showed a similar pattern in patients
(Figure 4A). The mean MNC-FE (0.596 0.4) and CD34-FE
(0.566 0.24, P5 0.55) in these patients were nearly identi-
cal (Figure 4B). Likewise, there was a linear correlation
between the MNC-FE and CD34-FE (Figure 4C, R5 0.68).
There was no correlation between CD34-FE, MNC-FE
and MNC content (%MNC) of the product. Three patients
showed an alternating pattern between CD34-FE and MNC-
FE (Figure 3S, Supporting Information), suggesting possible
technical issues with cell separation and interface stability.
3.7 | Femoral line removal
Femoral lines were removed 6–24 h after the last A-HPCC at
the bedside or in the operating room in conjunction with
TABLE 4 Incidence of CVC-associated AE during A-HPCC
Femoral CVC Thoracic CVC
a
(n5 75) Totala (n5 38) Pb Pediatricc (n5 19) Pb Adultsd (n5 19) Pb
No. patients access AE (%) 8 (10.7%) 12 (31.6%) 0.006 8 (42%) 0.0011 4 (21%) 0.23
Bleeding 3 (4%) 2 (5.3%) 0.76 1 (5.3%) 0.80 1 (2.6%) 0.80
Flow-related AEe 5 (6.7%) 10 (26.3%) 0.004 7 (37%) 0.0005 3 (15.8%) 0.20
Repeated flushing 2 (2.7%) 3 (7.9%) 2 (10.5%) 1 (5.3%)
Line reversal 2 (2.7%) 1 (2.6%) 0 1 (5.3%)
Slow inlet rate 2 (2.7%) 9 (23%) 6 (31.6%) 3 (15.8%)
Interface issues 1 (1.3%) 1 (2.6%) 1 (5.3%) 0
Alternate IV access 0 4 (10.5%) 2 (10.5%) 2 (10.5%)
Recirculation 0 1 (2.6%) 0 1 (2.6%)
Aborted procedure 0 3 (7.9%) 2 (10.5%) 1 (2.6%)
aAdult and pediatric patients with thoracic CVC.
bSignificance relative to pediatric femoral CVC patients by v2.
cPediatric other CVC: 10 subclavian, 9 internal jugular.
dAdult myeloma patients collected with thoracic (subclavian) CVC between 2010 and 2013.
eMore than one flow-related AE in some patients over the course of A-HPCC.
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another procedure. Approximately 37% (28/75) of patients
required a platelet transfusion before CVC removal due to
procedure-related platelet losses. An additional 6 patients
had received pre-procedure platelet transfusion on the day of
line removal. The mean platelet count prior to CVC removal
was 896 29 K lL21, with higher counts observed in trans-
fused patients (1046 35 vs. 816 22 K lL21; P5 0.02).
In 72/74 (97%) patients, there were no complications asso-
ciated with femoral CVC removal. Hemostasis was achieved
after 5–40 min (median time, 20 min) of direct pressure. There
was also no clear correlation between the platelet count and
time to hemostasis (Figure 4S, Supporting Information).
Patients who clotted within 20 min had platelet counts ranging
between 50 and 138 K lL21, whereas platelet counts >100
K lL21 were documented in four patients who required pres-
sure for 30 min or longer. Platelet transfusion did not shorten
the time to hemostasis (median time, 20 min in transfused and
nontransfused). Two patients experienced bleeding following
femoral CVC removal. In both patients, there was no evidence
of an underlying coagulopathy. The patients had normal liver
function and PT values. There was no history of an inheritable
clotting disorder. Neither patient was receiving systemic hepa-
rin or other anticoagulants.
One Patient (41 kg, 6-year-old female) underwent a sin-
gle A-HPCC collection with a post-procedure platelet count
of 44 K lL. She received a platelet transfusion prior to line
removal. Following removal, the CVC site was noted to
have prolonged oozing. The patient’s hospital stay was
FIGURE 3 Correlation between CD34-FE, peripheral CD34 and WBC counts in nine individual pediatric patients undergoing A-HPCC using a
femoral CVC. CD34-FE are plotted along the left y axis (—·—). Peripheral WBC (K lL21, -w-) and CD34 (CD34/lL, - -- -) are plotted along
the right y axis. Also shown are changes in G-CSF dosing and the addition of GM-CSF and plerixafor. Please note that in patients 17 and 50, plerixa-
for had been inadvertently administered in the early morning hours,< 6 h prior to A-HPCC. In Patient 55, plerixafor had been administered by IV
immediately prior to A-HPCC
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extended an additional night for observation. She was dis-
charged the following morning with no evidence of bleeding
or hematoma.
The second case involved a 12 kg, 3-year old who under-
went one A-HPCC, followed by line removal later that eve-
ning. The patient initially achieved hemostasis after 15 min
of pressure, but subsequently developed increased bleeding
that did not respond to pressure (80 min) and platelet transfu-
sion. Hemostasis was finally achieved after application of a
topical adhesive by Pediatric Surgery. A small hematoma
was noted the following morning. Post-procedure (4 h) labo-
ratory studies showed an adequate platelet count (84
K lL21), but a prolonged aPTT (119 seconds (s); normal
range, 22–32 s). A repeat aPTT was improved, but still ele-
vated (38.2 s). Of note, this patient had a long-term, tunneled
CVC for infusions and blood draws with multiple prolonged
aPTT, consistent with heparin-contamination.23
There were no reports of infection, thrombosis, limb swel-
ling, extravascular effusions, or arteriovenous fistulas associ-
ated with femoral CVC in any patient in this series.9,10,13
3.8 | Product sterility
There were no positive cultures in any product collected (0/
118). In a 10-year retrospective review of all pediatric A-
HPCC, only 4/338 (1.1%) products from 3/197 patients
FIGURE 4 Correlation between CD34-FE andMNC-FE in individual patients. (A) CD34-FE andMNC-FE values are plotted along the left (—·—)
and right (- -- -) y-axis, respectively. TheMNC content (%MNC) of the collected product is denoted along the X-axis. Line and flow related issues in three
patients (19, 49, 45) are also shown. (B)Mean CD34-FE andMNC-FE for all seven patients. (C) Linear correlation betweenMNC-FE and CD34-FE.
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(1.5%) were culture positive. Two products were collected
via femoral CVC for an estimated culture-positive rate of
0.7% per product and 1.2% per patient. In both cases, only
the post-processing sample was positive with a nonviable
organism after 11–14 days of culture, consistent with a lab
contaminant.
Two products from the same patient were culture positive
with coagulase-negative Staphylococcus within 5–7 days.
The patient, catheter tip, and products (pre- and post-process-
ing) were positive with coagulase-negative Staphylococcus.
This was considered a true positive attributed to a colonized
subclavian CVC (PowerLine®) placed 1 month earlier.7
4 | DISCUSSION
In this study, we describe our single-institution experience
using femoral CVC for stem cell collection in children,
including children as young as 10 months. Children typically
undergo femoral line placement in the morning of their first
scheduled A-HPCC. The vast majority (84%) of the children
in this series collected in one or two procedures with only
16% patients requiring a line for 3 or more days. CVC were
subsequently removed by BMT staff within 6–24 h after the
last A-HPCC. Hemostasis was achieved after 10–30 min of
pressure without complication in 97% patients. Only two
patients experienced prolonged bleeding, with one patient
developing a small hematoma. There were no patients who
experienced serious long-term sequlae following femoral
CVC placement.
Clinically, there were few issues with femoral CVC for
A-HPCC. A total of 10 AE were documented in 10.7%
patients and 8.4% procedures. AE were limited to mild
bleeding and flow-related AE, which were amendable to cor-
rection by routine maneuvers. This was significantly better
than the AE rate in 19 pediatric patients with thoracic CVC
(42%, P5 0.001). Pediatric patients with thoracic CVCs had
a significantly higher rate of flow-related AE and were more
likely to have prolonged procedures due to a slow inlet rate
(<0.7 mL min21 kg21), require alternate venous access,
and in two patients, early termination of the procedure
(Table 4).15 Finally, there were no confirmed cases of bacte-
rial contamination using femoral CVC in the last 10-years
whereas a tunneled thoracic CVC was linked to line-
associated bacterial contamination of two products.
These results are equivalent or better than those reported
in adults (Table 5).1,4,24–41 Shariatmadar and Noto reported
bleeding in 1/63 (1.6%) of autologous adult patients, with
no episodes of occlusion or flow-related AE, even after
6 days.24 In contrast, Moreiras-Plaza et al. encountered
catheter-related flow issues in 12% (29/232) of procedures
that were resolved by patient repositioning or reversing lines:
other AE included minor bleeding after insertion (2%) and
hematoma (15.8%).25 A larger study of 147 adults and 488
HPCC reported catheter-related AE rate in 5% of procedures
and 16.8% of patients. Documented AE included bleeding
and large hematomas requiring platelet transfusion or red
cell transfusion (6.8%); catheter malplacement, occlusion and
thrombosis (8.1%); arteriovenous fistulas (1.3%); and infec-
tion (0.6%).26 Breast cancer patients were particularly sus-
ceptible to thrombosis, with femoral vein thrombosis and
pulmonary embolism in 4.7% and 5.9% of patients, respec-
tively.27 More recently, Donmez observed a 1.8% occlusion
rate and 10.7% overall AE rate in 268 adults undergoing A-
HPCC, with bleeding and hematoma accounting for most
recorded AE (57%).28 In healthy donors, femoral CVC had a
8.7% AE rate due to catheter malfunction/malposition (3.5%)
and hematomas (5.2%).29 Product contamination rates using
femoral CVC in adults are approximately 1%.28
Although femoral CVC access is used by many centers
for pediatric HPCC,30,31,42,43 there is limited published data
regarding catheter performance. Yocco et al. anecdotally
reported a high incidence of alarms, obstructions and kinked
lines using femoral CVC in children <3 years of age,
TABLE 5 Literature review of CVC performance in pediatric and adult HPC collection
CVC Patient No. No. CVC-related AE (% patients [% procedures])
b
Reference location type patient HPCCa Flowb Bleedingb Other AEb
This study Femoral Pediatric 75 1 (1–6) 6% [5.3%] 4% [2.5%] 1.3% hematoma
2.6% bleeding post-removal
Sevilla30 Femoral Pediatric 12 1 (1–2) 0 0 8.3% hematoma
25% minor bleeding post-removal
Bolan31 Femoral Pediatric 31 1 na 3.2% 3.2% hematoma
Shariamatmadar24 Femoral Adult 63 1 (1–4) 0 1.6% [1.1%] none
Sohn29 Femoral Adult 57 1 (1–3) 3.5% [1.8%] 0 5.2% hematoma
(Continues)
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prompting them to use a soft leg splint to immobilize
patients.11 Sevilla et al. noted hematoma (8%) and bleeding
(25%) in 12 children under <10 kg.31 Kanold et al. reported
overall good performance in 14 children <15 kg, although
one patient developed an abscess.43 Bolan et al. used femoral
CVC in 80% (31/38) of pediatric patients, with serious
TABLE 5 (Continued)
CVC Patient No. No. CVC-related AE (% patients [% procedures])
b
Reference location type patient HPCCa Flowb Bleedingb Other AEb
Adorno26 Femoral Adult 147 3 (1–8) 8.1% [2.4%] na 6.8% hematoma
4.7% thrombosis
0.6% infection
1.3% arteriovenous fistula
Moreiras-Plaza25 Femoral Adult 95 2 (1–4) 30.5% [12%] 2% [0.9%] 15.8% hematoma
Donmez28 Femoral Adult 268 3 (1–8) 1.8% 0.7% [0.2%] 4.7% hematoma
0.7% bleeding post-removal
1.8% thrombosis
1% product contamination
Saif27 Femoral Adult 85 2 (1–4) 0 na 10.6% thrombosis post-removal
Madero32 Thoracic Pediatric 56 1 (1–3) 15% na 7% insertion AE
2.3% pneumothorax
Fishmeister4 Thoracic Pediatric 46 3 (1–10) 28% [20%] 0 0.6% infection
Orbach33 Thoracic Pediatric 24 2 (1–4) 16% 0
Gorlin1 Thoracic Pediatric 14 6 (3–8) 64% [16%] 0 7% pneumothorax
Diaz34 Thoracic Pediatric 31 1 (1–3) na na 3.2% pneumothorax
Salazar-Riojas35 Thoracic Pediatric 22 1 (1–2) 0 0 none
This study Thoracic Pediatric 19 2 (1–4) 37% [24%] 6% [5.3%] 5.2% hematoma
Goldberg36 Thoracic Adult 75 1 (1–6) 16% na 1.3% pneumothorax
1.3% cardiac tamponade
50% thrombolytic therapy
2.3% procedure aborted
Alegre37 Thoracic Adult 110 2 (1–13) 1.8% na 1% pneumothorax
3.6% infection
Meisenberg38 Thoracic Adult 156 na 10.2% na 3.6% pneumo/hemothorax
5.7% thrombosis
7% infection
Hahn39 Thoracic Adult 153 4 (2–12) 5.2% [1.1%] na 5% thrombosis
3% infection
2% hematoma
0.6% pneumothorax
Papadimitriou40 Thoracic Adult 72 1 (1–2) 6% [5.3%] na na
Reik24,41d Thoracic Adult 88 2 (1–5) 21% [13%]d na na
aThe median (range) of HPCC procedures performed.
bThe percent patients and [% HPCC procedures] with documented CVC-related AE. Flow-AE and bleeding AE refer to occlusion and bleeding during leukaphere-
sis. Other AE include AE associated with catheter insertion, catheter removal, infection and thrombosis.
cna, not available.
dReik et al. documents a 13% occlusion rate among 88 patients.41 A subsequent publication from the same group states that all the documented flow-related AE
were in patients with subclavian CVC.24
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bleeding and hematoma formation in one patient who under-
went LVL (5 BV) with heparin anticoagulation.30 In pediat-
ric ICU patients, similar rates of bleeding (5–9%) and
hematoma (3%) have been reported, although the incidence
of catheter obstruction and thrombosis were higher (11–
28%).9,10
We also examined femoral CVC performance over time
for the entire population, as well as individual patients. In
general, the mean FE was stable over the course of A-
HPCC, despite significant day–day variability in individual
patients. Two patients required reversal of arterial and
venous lines, which has been reported to increase recircula-
tion approximately three-fold during dialysis.44,45 and
decrease CD34-FE in A-HPCC.30 This was a major concern
since femoral CVC have a higher base-rate of recirculation
relative to thoracic CVC.46,47 Although both patients experi-
enced a decrease in CD34-FE (22%, 60%), it is difficult to
attribute the decrease to recirculation given the normal intra-
patient variation observed in our patient cohort.
One interesting observation was the apparent drop in
CD34-FE 12–24 h after receiving plerixafor in many
patients. The findings were unexpected and are difficult to
explain. Plerixafor is not considered prothrombotic or proin-
flammatory.48 In animal models, plerixafor can moderate
inflammatory immune disorders, decrease fibrosis, and pro-
mote revascularization.49 However, plerixafor is associated
with an increase in peripheral WBC counts that is independ-
ent and synergistic with G-CSF.48,49 The latter could theoret-
ically impact CD34-FE due to the inverse exponential
relationship between peripheral WBC and CD34-FE.18,50,51
In adult myeloma patients, peripheral WBC >20–35 K lL21
have been reported to depress CD34-FE,18,50 with some cen-
ters dictating a slower inlet rate at high peripheral WBC.51 In
our limited pediatric series, most (7/9, Figure 3) patients had
relatively modest peripheral WBC counts after plerixafor
(range, 10–22 K lL21). There was no consistent correlation
between CD34-FE, peripheral WBC, or platelet count in
these patients.
Our study shows the safety and good performance char-
acteristics of femoral double-lumen polyurethane dialysis
CVC in pediatric HPCC, especially in small and very young
children. Access options used in this population include dou-
ble and single lumen CVCs (silicon, polyurethane), radial
artery catheters, and PIVs.1,4,33,52,53 Long-term, silicone
CVCs are soft and would appear to be an attractive option in
young children; however, they are prone to collapse under
the negative pressure encountered during automated aphere-
sis.1 Moreover, the risk of mechanical occlusion increases
with decreasing lumen size, leading one investigator to rec-
ommend a 10 French or larger when using silicone CVCs.1
Fishmeister et al. compared long-term, tunneled, silicone
CVCs (7–12 French) in 51 children and young adults under-
going A-HPCC.4 Low inlet rates, reversal of draw and return
lines, and line occlusion occurred in 28% of patients and
20% of procedures. Furthermore, patients still required PIV
for return to avoid recirculation due to the close proximity of
the draw and return lumens. Likewise, Orbach observed a
23% occlusion rate during HPCC using pre-existing thoracic
CVC.33 Finally, long-term, CVCs have an increasing risk of
thrombosis, dysfunction and infection over time.5–8 As noted
earlier, the only case of true bacterial infection and product
contamination in our pediatric population was associated
with a tunneled, subclavian CVC.
Femoral CVCs may have other advantages in young chil-
dren relative to subclavian and internal jugular CVC. Subcla-
vian lines have a lower success rate for insertion (87% versus
94% femoral CVC), with 26–40% of children experiencing
an AE.9,10 Furthermore, bleeding complications arising dur-
ing cannulation and insertion of subclavian and internal jugu-
lar lines can be difficult to manage, leading to hemothorax,
cardiac tamponade and even death.8 Other complications of
thoracic CVC are pneumothorax, cutaneous emphysema, air
embolism, brachial plexus injury, and cardiac arrhythmias
(Table 5).1,3,32–39,54 As noted by Gorlin,1 very young chil-
dren may be particularly susceptible to cardiac arrhythmias
due to their small anatomy relative to catheter length, leading
to a significant risk of the tip extending deep into the right
atrium with mechanical irritation of the sinoatrial node.1,3
Finally, thoracic CVC are associated with greater intra-
procedure decreases in blood pressure during apheresis
procedures.55
Subclavian CVCs also have 15% incidence of catheter
malposition and dysfunction.9,10,56 with flow-related issues
in 3–64% of patients (Table 5). This is particularly true of
left subclavian CVCs, which have a 16–50% AE rate during
A-HPCC and account for 19% of severe procedure-related
AE at our institution.15,38,57–60 The increased length associ-
ated with left subclavian lines inherently increases resistance
to flow and the potential for anatomic obstruction.57 The dis-
tal tip can either adhere along the lateral superior vena cava
with intermittent occlusion, or reflect back into the left
brachial cephalic vein with intravascular knotting.4,57
In summary, we report our experience using short-term
femoral CVC for A-HPCC in young children. Femoral CVC
provided adequate venous access with few flow-related
alarms or complications when compared to thoracic CVC in
our pediatric population. Our experience with femoral CVC
for A-HPCC is equivalent or better than that reported in
adults.24–29 Potential disadvantages of femoral CVC are
mobility restrictions due to risk of catheter kinking, breaking
or disconnection; vessel injury, thrombosis, and infec-
tion.11,61 Studies in adults, however, have shown that pa-
tients with femoral lines can undergo limited physical
activities (sitting, standing, limited walking) without CVC-
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related AE.61 In addition, femoral and thoracic CVC place-
ment in young children typically require anesthesia,42,62
which has a reported 2–3% complication rate in this popula-
tion,62 although none of our patients experienced anesthetic
complications associated with femoral CVC insertion. Inher-
ent limitations of our findings is the single institution, retro-
spective study design. Nonetheless, to our knowledge, this is
the first study to report an in-depth analysis of femoral CVC
performance and outcomes in pediatric A-HPCC in a moder-
ately large cohort of young children.
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